J Lab Med Qual Assur 2017; 39(2): 83-89
Published online June 30, 2017
Copyright © Korean Association of External Quality Assessment Service.
Misuk Ji1, Hee-Won Moon2, Seungman Park3, Mina Hur2, Yeo-Min Yun2
1Department of Laboratory Medicine, Veterans Health Service Medical Center, Seoul, Korea,
2Department of Laboratory Medicine, Konkuk University School of Medicine, Seoul, Korea,
3Green Cross Laboratories, Yongin, Korea
윤여민 우)05030 서울시 광진구 능동로 120-1, 건국대학교 의학전문대학원 진단검사의학과 Tel: 02)2030-5582, Fax: 02)2030-5587, E-mail: email@example.com
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
B-type natriuretic peptide (BNP) levels are elevated in various conditions unrelated to heart failure, such as acute coronary syndrome, and cardiac troponin (cTn) levels may also be elevated in several non-ischemic conditions. This study aimed to evaluate the clinical usefulness of combined cardiac marker testing (BNP and cTnI) with point-of-care devices in patients who presented to the emergency department (ED). Two thousand six hundred and seventy-four consecutive patients who visited the ED from March to August 2013 were included in this study. Cardiac marker testing was performed using the Triage Cardio3 panel (Alere, USA). Electronic medical records were collected on August 2014. We found that 22.2% patients had elevated BNP and/or cTnI (12.8% with only elevated BNP, 4.4% with only elevated cTnI, and 5.0% with both elevations). Patients with elevations in both marker levels showed significantly higher admission rate (78.5% vs. 62.7%, Concurrent elevation of BNP and cTnI may be associated with inferior clinical outcome and combined testing of cTnI and BNP levels with high sensitivity would provide important information for assisting management decisions at the ED.
B-type natriuretic peptide (BNP) levels are elevated in various conditions unrelated to heart failure, such as acute coronary syndrome, and cardiac troponin (cTn) levels may also be elevated in several non-ischemic conditions. This study aimed to evaluate the clinical usefulness of combined cardiac marker testing (BNP and cTnI) with point-of-care devices in patients who presented to the emergency department (ED).
Two thousand six hundred and seventy-four consecutive patients who visited the ED from March to August 2013 were included in this study. Cardiac marker testing was performed using the Triage Cardio3 panel (Alere, USA). Electronic medical records were collected on August 2014.
We found that 22.2% patients had elevated BNP and/or cTnI (12.8% with only elevated BNP, 4.4% with only elevated cTnI, and 5.0% with both elevations). Patients with elevations in both marker levels showed significantly higher admission rate (78.5% vs. 62.7%,
Concurrent elevation of BNP and cTnI may be associated with inferior clinical outcome and combined testing of cTnI and BNP levels with high sensitivity would provide important information for assisting management decisions at the ED.
Keywords: Troponin I, B-type natriuretic peptide, Emergency department
B-type natriuretic peptide (BNP) is synthesized in the ventricular myocardium and released into circulation in response to ventricular dilatation and pressure overload . In addition to its roles in the diagnosis, exclusion, and risk stratification of congestive heart failure, BNP can also provide prognostic information in patients with acute coronary syndrome (ACS) [1-3]. Higher BNP levels predict higher risk for death due to post-myocardial infarction and heart failure independent of the status of troponin . Cardiac troponins (cTn) are both sensitive and specific markers of cardiac myonecrosis, and higher levels predict worse outcomes [4-6]. cTn is also elevated in many non-ischemic conditions, including acute and chronic heart failure, myocarditis, critical illness, and sepsis . Elevated cTn levels correlate with adverse prognosis in patients without ACS. cTn values above the 99th percentile of the upper reference limit are suggested as prognostic markers in patients with acute decompensated heart failure  or other heart failure .
Accordingly, the implementation of multiple biomarker approach, including both cTn and BNP, might be considered in patients with possible ACS at the emergency department (ED). Several point-of-care (POC) devices for cardiac marker testing are currently in use at various sites, including the ED, due to rapid turnaround time and users’ convenience [9,10]. This study aimed to evaluate the clinical usefulness of combined cardiac marker testing with a POC device in unselected patients who present to the ED.
From March to August 2013, adult patients (over 18 years-old) who visited the ED of the Konkuk University Medical Center and received simultaneous BNP and cTnI testing with a POC device were included in this study. A total of 2,674 patients were enrolled, and they had symptoms or signs of possible ACS or risk factors. The mean age of all patients was 58.9 years. The institution is a tertiary care community hospital located in Seoul with approximately 50,000 annual ED visits. This study was approved by the institutional review board of the Konkuk University Medical Center (approval no. KUH1200035).
BNP and cTnI were measured by the Triage Cardio3 panel (Alere, San Diego, CA, USA) with a Triage meter device. Cutoff value of BNP was 100 pg/mL [11,12]. For cTnI, the 99th percentile value was 0.02 ng/mL and the cutoff for determination of clinical sensitivity was 0.4 ng/mL according to the manufacturer’s guidelines [11,12]. cTnI values ≥0.03 ng/mL were considered as elevated cTnI, whereas those between 0.03 and 0.4 ng/mL were interpreted as low-level positive, which is indicative of marginally increased cTnI levels . cTnI values above 0.4 ng/mL were interpreted as overtly positive. The cTnI results were divided into 3 groups (negative, low-level positive, and overtly positive). Creatine kinase-myocardial band results were not included in this study. For cTnI, total coefficient of variation at the 99th percentile was 17.0%, and hence, this assay was clinically usable according to the Apple scorecard [14,15].
Patients’ electronic medical records including diagnosis at the time of admission, admission rate, length of stay, rate of readmission within 3 months, and mortality rates were retrospectively collected on August 2014. Patients showing any positivity for cTnI or BNP were reviewed.
The IBM SPSS Software ver. 19.0 (IBM Corp., Armonk, NY, USA) was used for statistical analysis. The independent
The study participants were divided into 4 categories according to the results of cardiac marker testing: BNP elevation only (343, 12.8%), cTnI elevation only (118, 4.4%), both elevations (135, 5.0%), and both negative (2,078, 77.7%) (Fig. 1). In total, 22.3% patients had elevated BNP and/or cTnI. The mean age of these patients was significantly higher than those of subjects who tested negative for both markers (70.7±14.2 versus 54.9±18.4 years,
Distribution of patients based on the positivity for two cardiac markers. Five hundred and ninety-six patients (22.3%) had elevated BNP and/or cTnI concentrations. The 99th percentile of cardiac troponin I is 0.02 ng/mL, and hence, values ≥0.03 ng/mL were considered to be positive. The cutoff for BNP is 100 pg/mL. Abbreviations: BNP, B-type natriuretic peptide; cTnI, cardiac troponin I.
Patients with elevations in both marker levels revealed higher admission rate after the ED visit (78.5% versus 62.7%,
Admission rate and length of hospital stay after admission of each group based on the combinatin of cTnI and BNP levels. Length of hospital stay presented as median value and interquartile ranges are as follows: 5–19, 3–13, and 5–20 days for both positive, cTnI positive only, and BNP positive only groups, respectively. Abbreviations: cTnI, cardiac troponin I; BNP, B-type natriuretic peptide.
The diagnosis at the time of admission was categorized into organ-based major groups. For patients with double elevations (N=105), cardiovascular disease (N=43, 41.0%) was most common, followed by respiratory disease (N=18, 17.1%) and gastrointestinal disease (N=11, 10.5%). The most common diagnosis of a single disease was heart failure (N=16), followed by ACS (N=13), and pneumonia (N=12). For patients with only cTnI elevation (N=74), cardiovascular disease (N=30, 40.5%) was the most common disease, followed by neurological (N=20, 27.0%), respiratory (N=7, 9.5%), and gastrointestinal diseases (N=7, 9.5%). The most common diagnosis of a single disease was ACS (N=20), followed by cerebral infarction (N=6), and stable angina (N=5). For patients with only BNP elevation (N=231), cardiovascular disease (N=48, 20.8%) was the most common affliction, followed by gastrointestinal (N=46, 19.9%), respiratory (N=42, 18.2%), neurological (N=39, 16.9%), and renal diseases (N=27, 11.7%). The most common diagnosis as a single disease was pneumonia (N=29), followed by heart failure (N=19), cerebral infarction (N=19), chronic kidney disease (N=14), and cholangitis (N=10).
Among the 253 patients with elevated cTnI (sole cTnI elevation and concurrent BNP elevations together), 212 patients (83.8%) showed low-level positivity. In this subgroup, patients with elevations in both markers were also hospitalized more at the ED (76.7% versus 59.4%,
In this study, we determined whether simultaneous measurements of BNP and cTnI were relevant at the ED where time is critical and enough data about patients is unavailable in many cases. We found that the hospital course of the patients with elevations in both biomarkers appeared to be different compared to those with elevations in levels of only cTnI or BNP. The multiple marker approach can provide additional information regarding the simultaneous elevation of the marker levels, other than assisting in the diagnosis/exclusion of ACS in cases of possible heart failure.
The ED physician might have considered the clinical status of patients positive for both the markers to be more serious, which might have increased the admission rate (Table 1 and Fig. 2). The length of hospital stay after admission was longer in patients with double elevations compared to those with cTnI only elevation, but similar to those with BNP only elevation. This might be related to chronicity of disease or relatively older mean age (>70 years) in patients with BNP elevation. Among patients with cTnI elevation, certain findings such as higher admission rate and longer length of hospital stay were still observed when the patients with low-level positive cTnI (0.03-0.40 ng/mL) were only included in the analysis. This level of elevation can be observed in various clinical situations, and the patients are relatively heterogeneous in terms of their afflictions compared to those with overtly positive cTnI levels.
POC testing of cTnI and BNP may assist the ED physicians in prompt triage, accurate diagnosis, and management of patients due to rapid delivery of the results within 15-20 minutes with comparable sensitivity and specificity [9,10,16]. POC testing of cTn1 has also resulted in a substantial lowering of charges per patient admission in a metropolitan medical center of the USA, although in a small number of patient [10,17]. In this study, about one of five patients (22.3%, 596/2,674) who visited the ED of the university hospital and underwent POC testing showed positive cTnI and/or BNP result. Our patients might represent a mixed population with variable clinical situations, although each hospital may be identified by specific patient characteristics. The positive rates for cTn or BNP differ according to the patient population and cutoff used [13,16]. Troponin (cutoffs 1.0 and 0.1 ∞g/L for cTnI and cTnT, respectively) was positive in 6.2% patients with acute decompensated heart failure, and BNP (cutoff 80 pg/mL) was positive in 10.6% patients with ST-segment elevation myocardial infarction in previous studies [18,19].
This study has several limitations. First, we did not review the medical records of the patients who were negative for both the markers in detail. Therefore, the admission rates of the cTnI-negative and the BNP-negative group could not be calculated. In addition, other factors affecting admission rate and hospitalization period were not assessed. Second, this study was retrospective in design. Third, positive BNP results could be due to decreased renal function such as chronic kidney disease. Fourth, we could not compare the results of the central laboratory with those of POC testing.
In conclusion, we observed that patients with concurrent elevations of BNP and cTnI may be associated with inferior clinical outcome. Combined and sensitive testing of cTnI and BNP would provide additional information for patients with suspected ACS and aid in the identification of heart failure. In addition, it would assist in excluding ACS in patients with suspected heart failure, which can be helpful for management decisions.
|View Full Text||PubReader|
|Abstract||Print this Article|
|E-mail alert||Export to Citation|
|Article as PDF||Open Access|